Ischemic Heart Disease.  Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual.

Slides:



Advertisements
Similar presentations
M YOCARDIAL ISCHEMIA Prepared by: Dr. Nehad Ahmed.
Advertisements

The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE FEBRUARY 10,2110.
ANGINA PECTORIS. Angina pectoris (chest pain) is the result of myocardial ischemia caused by an imbalance between myocardial blood supply and oxygen demand.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 51 Drugs for Angina Pectoris.
Chronic stable angina Dr Taban Internist & cardiologist.
B) Drug Therapy (Antihypertensives) ACEi B.B CCB D iuretics. Centrally acting agents: alphametyldopa, HTN + pregnancy.
Management of Stable Angina Pectoris David Putnam, MD Albany Medical College.
Ischemic Heart Disease
Coronary Artery Disease. What is coronary artery disease? A narrowing of the coronary arteries that prevents adequate blood supply to the heart muscle.
Ischemic heart disease
Ischemic Heart Diseases IHD
Angina and MI.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
ISCHEMIC HAERT DISEASES BY DR\ RAMY A. SAMY. Ischemic Heart Disease  Hypoxemia (diminished transport of oxygen by the blood) less deleterious than ischemia.
EMS 353. Lectures 6 Dr. Maha Khalid physiology of pharmacology cardiovascular system.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
Dr Jayachandran Thejus.  Coronary artery disease-  Block in coronary artery due to plaque or thrombus  Leads to myocardial ischemia manifested as chest.
1 ANGINA ANGINA MYOCARDIAL OXY. DEMAND >. OXY. SUPPLY. OXY. SUPPLY < SYMPTOMS – chest pain mostly relieved by taking rest, dyspnea, sweating, nausea..
Clinical case no. 22 Presenter: Lin,Huei-Hsiu (Caroline) (Caroline)
Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.
Coronary Artery Disease Presented by: Marissa V. Dacumos Batch 17
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
2. Ischaemic Heart Disease.
Ischaemic Heart Disease. Aims and Objectives n Ischaemic heart disease –Definition, manifestations, epidemiology, aetiology, pathophysiology, risk factors.
Drug Treatment of Ischemic Heart Disease Fixed "Stable" Angina Variant Angina Unstable Angina Myocardial Infarction.
Angina & Dysrhythmias. A & P OF THE CARDIAC SYSTEM Cardiac output  CO=SV(stroke volume) X HR(heart rate) Preload  Volume of blood in the ventricles.
Antianginal drugs Angina pectoris is the severe chest pain that occurs when coronary blood flow is inadequate to supply the oxygen required by the heart.
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm. Due to imbalance between myocardium oxygen requirement and.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
Elsevier items and derived items © 2009 by Saunders, an imprint of Elsevier Inc. Coronary Artery Disease Coronary artery disease: A condition involving.
Non-communicable Disease Coronary Heart Disease
1 3 rd jan 2009 Done by: Ahmed M. Aljabri Pharm.D.
Ischemic heart diseases Ischemia : it is inadequate supply of O2 to an organ or tissue (result from inadequate blood flow) insufficient to meet the organ’s.
Drugs used in angina pectoris
Dr. Sohail Bashir Sulehria
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Antianginal drugs Antidysrrhytmic drugs
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm & neck. Due to imbalance between myocardium oxygen requirement.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Myocardial Infarction Angina Pectoris What is an MI?
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.1 Drugs for Angina Pectoris.
Drugs for Angina Pectoris
PHARMACOLOGY OF ANTI-ANGINAL DRUGS (ID#580) Dr. Mariam Yousif Pharmacology & Toxicology Dept. November 17 th, 2014.
ANGINA PECTORIS Classic angina is characterized by substernal squeezing chest pain, occurring with stress and relieved with rest or nitroglycerin. May.
ISCHEMIC HEART DISEASE
Ranolazine The mechanism of action of ranolazine has not been determined, but it may be related to reduction in calcium overload in ischemic myocytes.
Ischemic Heart Disease
CORONARY ARTERY DISEASE
21 Drugs For Angina Pectoris, Myocardial Infarction, And Cerebrovascular Accident.
Management of ST-Elevation Myocardial Infarction
Ischemic Heart Disease
Angina Pectoris Prepared by : Ansam Sharef Ahmad Aswad.
Hypertension (High Blood Pressure)
Unstable Angina and Non–ST Elevation Myocardial Infarction
New Paradigm of Anti Anginal Therapy dr.Yerizal Karani SpPD,SpJP(K)
Nursing Management: Patients With Coronary Vascular Disorders
Chapter 28 Management of Patients With Coronary Vascular Disorders
Antianginal Drugs Ischemic Heart Disease Angina pectoris
Focus: Lipids and the endothelium
Coronary Artery Disease and Acute Coronary Syndrome
Antianginal Drugs.
Drugs Used to Treat Angina Pectoris
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Ischemic Heart Disease

 Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual may cycle between over the course of several decades. These phases includes asymptomatic disease, stable angina, progressive angina, unstable angina, non st segment elevation MI, and St segment elevation MI

 Stable angina (SA)  Acute myocardial infarction (AMI)  Unstable angina / non ST segment elevation myocardial infarction (UA/STEMI)

 Required reading  Dipiro  ischemic heart disease  Uncomplicated myocardial infarction ACC/AHA joint guidelines ter.jhtml?identifier=  2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina

 Go and read about  Definition of myocardial ischemia  Pathophysiology and etiology of ischemic heart disease  Anatomy of coronary circulation  Epidemiology  Definition and pathophysiology, clinical presentation of  stable angina pectoris,  variant angina,  silent myocardial ischemia,  syndrome X,

 Diagnosis procedures of ischemic heart disease  History and physical examination  Electrocardiogram  Exercise stress testing  Exercise electrocardiography  Radionuclide imaging  Pharmacologic stress testing  Echocardiography  Cardiac imaging  Cardiac catheterization and coronary angioplasty

 Based on the manifestation a patient is experiencing, some therapies may be added or modified however, several basic treatment rules apply to all individuals with CAD refardless of the symptoms he or she may expeience  ABCDE!

 Management!  How to use guideline…. chronic_angina_11_13_07.pdf

 A aspirin and antiplatelets  B beta-blockers and blood pressure  C cigarette smoking and cholesterol  D diet and diabetes  E education and exercise

Antiplatelets  Aspirin  Indicated in all patients with CAD unless contraindicated  mg/day  Decrease CV events by 1/3  Inhibits synthesis of thromboxane A2

Antiplatelets  Clopidogril  75 mg/day is aspirin absolutely CI  Magnitude of benefit not clear, one study suggests its benefits approximate those of aspirin  Prevents adenosine diphosphate ADP mediated platelets activation

Antiplatelets  Dipyridamole:  should be avoided in symptomatic CAD  Increase exercise induced M.ischemia  No benefit over aspirin

Lipid lowering therapy  LDL reduction to al least 100 mg/dl  Goal of less than 70 mg/dl in some patients

Angiotensin converting enzyme inhibitors  Specifically ramipril 10 mg/day greatly decrease CV events in patients with CAD (and no LV dysfunction) at high risk of subsequent CV events  An ACEI should be used in all patents with CAD  Postulated mechanisms: plaque stabilization, specifically via “ tissue ACE” inhibition

Therapies proven to not be beneficial in patients with CAD  Vitamin D  Hormone replacement therapy  Antibiotic therapy

 Goal:  Reduce symptoms of ischemia, increase physical function, and improve quality of life  Achieved by:  Decrease myocardial demand  Increasing myocardial oxygen supply

5) Beta Blockers  Pharmacologic effects  decrease inotropy and heart rate (decrease oxygen demand)  Goal resting HR BPM  Goal exercise HR of no more than 75 % HR associated with angina symptoms  CI  severe brdaycardia, high degree AV block, sick sinus syndrome (without pacemaker) and unstable systolic dysfunction

6) Calcium antagonists  Pharmacologic effects  Decrease coronary vascular resistance and increase coronary blood flow (increase oxygen supply)  Negative inotropy to varying degree nifidipine much more than amlodipine and felodipine ( decrease oxygen demand)  Decrease heart rate verapamil/diltiazem much more than non dihydropyridine

6) Calcium antagonists  Place in therapy  Added on BB therapy to achieve HR goal  Instead of BB therapy when unacceptable adverse effects emerge  Short acting CCB (nifidipine, nisoldipine) have been associated with increase CV event and should be avoided (except inn slow release formulation)

6) Calcium antagonists  CI  overt decompenstaed HF,  sever bradycardia,  high degree AV block and  sick sinus syndrome (without pacemaker)

7) Nitroglycerin  Pharmacologic effect  Via endothelium dependent VD, dilate epicardial arteries and collateral vessels (increase oxygen supply)  Decrease LV volume, due to decrease preload mediated by venodialation (decrease oxygen demand)

7) Nitroglycerin  Place in therapy  A scheduled nitrate is useful in conjunction with BB  PRN SL or spray nitrate is necessary to relieve efforts or rest angina  PRN nitrates can also be used before exercise to avoid ischemic episodes  CI  hypertrophic obstructive cardiomyopathey,  sever aorteic valve stenosis,  sildenafil within 24 hours